Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer.
FGFR3
PCR
TERT promoter
UroVysion
bladder cancer
cell-free DNA
liquid biopsy
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
03
2020
accepted:
20
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Recent studies showed the clinical utility of next-generation sequencing of urinary cell-free DNA (cfDNA) from patients with urothelial bladder cancer (UBC). In this study, we aimed to develop urinary cfDNA analysis by droplet digital PCR (ddPCR) as a high-throughput and rapid assay for UBC detection and prognosis. We analyzed urinary cfDNA of 202 samples from 2 cohorts. Test cohort was designed for investigating clinical utility of urinary cfDNA, and was composed of 74 samples from patients with UBC, and 52 samples of benign hematuria patients. Validation cohort was designed for validation and assessment of clinical utility comparing urinary cfDNA with UroVysion (Abbott, Illinois, USA), and was composed of 40 samples from patients with UBC, and 36 prospectively collected samples from patients under surveillance after surgery for urothelial carcinoma. We performed ddPCR analysis of hotspot gene mutations (
Identifiants
pubmed: 32509577
doi: 10.3389/fonc.2020.00755
pmc: PMC7250242
doi:
Types de publication
Journal Article
Langues
eng
Pagination
755Informations de copyright
Copyright © 2020 Hayashi, Fujita, Matsuzaki, Eich, Tomiyama, Matsushita, Koh, Nakano, Wang, Ishizuya, Kato, Hatano, Kawashima, Ujike, Uemura, Imamura, Netto and Nonomura.
Références
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267
pubmed: 28982750
Urology. 2003 Jan;61(1):109-18; discussion 118
pubmed: 12559279
Cancer Discov. 2016 Nov;6(11):1212-1214
pubmed: 27807101
Mod Pathol. 2019 Oct;32(10):1544-1550
pubmed: 31028363
Virchows Arch. 2016 Oct;469(4):427-34
pubmed: 27520411
Transl Androl Urol. 2019 Dec;8(Suppl 5):S497-S501
pubmed: 32042630
BJU Int. 2019 Sep;124(3):532-544
pubmed: 31077629
Genes Dev. 2015 Nov 1;29(21):2219-24
pubmed: 26515115
Nat Commun. 2013;4:2185
pubmed: 23887589
Front Oncol. 2019 Nov 19;9:1266
pubmed: 31803629
J Mol Diagn. 2000 Aug;2(3):116-23
pubmed: 11229514
Virchows Arch. 2017 Dec;471(6):761-767
pubmed: 28597078
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Science. 2017 Sep 29;357(6358):1416-1420
pubmed: 28818973
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Int J Urol. 2019 Nov;26(11):1044-1053
pubmed: 31370109
Cancer Discov. 2019 Apr;9(4):500-509
pubmed: 30578357
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Elife. 2018 Nov 12;7:
pubmed: 30418154
Cancer Res. 2013 Dec 15;73(24):7162-7
pubmed: 24121487
BJU Int. 2014 Sep;114(3):354-9
pubmed: 24128299
Urology. 2005 Dec;66(6 Suppl 1):35-63
pubmed: 16399415
Cancer Sci. 2019 May;110(5):1771-1779
pubmed: 30887605
Eur Urol. 2005 Jun;47(6):736-48
pubmed: 15925067
J Urol. 1992 Nov;148(5):1413-9
pubmed: 1433540
Eur Urol. 2017 Dec;72(6):952-959
pubmed: 28583311